Table 1. Efficacy of bortezomib and... | American Society of Hematology

Table 1.

Efficacy of bortezomib and thalidomide in DLI-refractory patients

Patient	Stem cell source	No. DLIs (maximum T-cell dose, T cells/kg)	Interval DLI next therapy, mo	Reason to add treatment	Next therapy	Response	Response, mo	Toxicity
1	Sibling	2 (1 × 10⁸)	5	NR to DLI	Bort 6	PR	6	No
2	Sibling	3 (1 × 10⁸)	4	NR to DLI	Bort 8	VGPR	8+	PNP grade 2
3	Sibling	2 (1 × 10⁷)	5	NR to DLI	Bort 3	PR	3	PNP grade 3; reason to stop therapy
4	MUD	2 (1 × 10⁷)	5	NR to DLI	Bort 8	VGPR	9	PNP grade 2
5	Sibling	1 (1 × 10⁷)	4	NR to DLI	Thal 100	PR	9+	GVHD grade 1; death from lung embolus
6	Sibling	1 (1 × 10⁷)	4	NR to DLI	Thal 200	PR	6+	GVHD grade 1
15	Sibling	1 (1 × 10⁶)	5	NR to DLI	Bort 8	PR	9+	PNP grade 2, dose reduction after cycle 3
28	Sibling	1 (1 × 10⁷)	15	Relapse from CR	Thal 100 + bort 4	CR	19+	No
29	Sibling	1 (1 × 10⁷)	21	Relapse from CR	Thal 100 + bort 4	CR	8+	No
32	MUD	1 (1.3 × 10⁷)	6	NR to DLI	Thal 100	PR	8	No
35	MUD	2 (1 × 10⁶)	2	NR to DLI	Thal 300	PD	NA	No
37	Sibling	1 (1 × 10⁶)	4	NR to DLI	Thal 100-300	PD	NA	No
39	Sibling	2 (5 × 10⁶)	3	NR to DLI	Thal 100-200	PR	7	No
39	Sibling	2 (5 × 10⁶)	10	PD after thal	Bort 4	CR	6	No
41	MUD	1 (5 × 10⁶)	5	NR to DLI	Thal 100	PR	24+	No
49	Sibling	1 (1 × 10⁶)	2	NR to DLI	Thal 200	PR	14	No
54	MUD	1 (1 × 10⁷)	4	NR to DLI	Bort 6	PR	6	No
59	Sibling	2 (1 × 10⁸)	1	NR to DLI	Thal 100	NR	NA	No
59	Sibling	2 (1 × 10⁸)	3	PD after thal	Bort 3	PD	NA	PNP grade 2
63	Sibling	3 (1 × 10⁸)	14	NR to DLI	Bort 8	MR	10	No
63	Sibling	3 (1 × 10⁸)	40	PD after bort	Thal 100	PR	15+	PNP grade 2

Patient	Stem cell source	No. DLIs (maximum T-cell dose, T cells/kg)	Interval DLI next therapy, mo	Reason to add treatment	Next therapy	Response	Response, mo	Toxicity
1	Sibling	2 (1 × 10⁸)	5	NR to DLI	Bort 6	PR	6	No
2	Sibling	3 (1 × 10⁸)	4	NR to DLI	Bort 8	VGPR	8+	PNP grade 2
3	Sibling	2 (1 × 10⁷)	5	NR to DLI	Bort 3	PR	3	PNP grade 3; reason to stop therapy
4	MUD	2 (1 × 10⁷)	5	NR to DLI	Bort 8	VGPR	9	PNP grade 2
5	Sibling	1 (1 × 10⁷)	4	NR to DLI	Thal 100	PR	9+	GVHD grade 1; death from lung embolus
6	Sibling	1 (1 × 10⁷)	4	NR to DLI	Thal 200	PR	6+	GVHD grade 1
15	Sibling	1 (1 × 10⁶)	5	NR to DLI	Bort 8	PR	9+	PNP grade 2, dose reduction after cycle 3
28	Sibling	1 (1 × 10⁷)	15	Relapse from CR	Thal 100 + bort 4	CR	19+	No
29	Sibling	1 (1 × 10⁷)	21	Relapse from CR	Thal 100 + bort 4	CR	8+	No
32	MUD	1 (1.3 × 10⁷)	6	NR to DLI	Thal 100	PR	8	No
35	MUD	2 (1 × 10⁶)	2	NR to DLI	Thal 300	PD	NA	No
37	Sibling	1 (1 × 10⁶)	4	NR to DLI	Thal 100-300	PD	NA	No
39	Sibling	2 (5 × 10⁶)	3	NR to DLI	Thal 100-200	PR	7	No
39	Sibling	2 (5 × 10⁶)	10	PD after thal	Bort 4	CR	6	No
41	MUD	1 (5 × 10⁶)	5	NR to DLI	Thal 100	PR	24+	No
49	Sibling	1 (1 × 10⁶)	2	NR to DLI	Thal 200	PR	14	No
54	MUD	1 (1 × 10⁷)	4	NR to DLI	Bort 6	PR	6	No
59	Sibling	2 (1 × 10⁸)	1	NR to DLI	Thal 100	NR	NA	No
59	Sibling	2 (1 × 10⁸)	3	PD after thal	Bort 3	PD	NA	PNP grade 2
63	Sibling	3 (1 × 10⁸)	14	NR to DLI	Bort 8	MR	10	No
63	Sibling	3 (1 × 10⁸)	40	PD after bort	Thal 100	PR	15+	PNP grade 2

Bort n indicates that patients received an intravenous bolus of bortezomib (1.3 mg/m²) on days 1, 4, 8, and 11 for n 3-week cycles; MUD, matched unrelated donor; Thal, thalidomide; PNP, polyneuropathy; GVHD, graft-versus-host disease; NR, no response; MR, minor response; PR, partial response; VGPR, very good partial response; CR, complete response; PD, progressive disease; NA, not applicable; and No, no WHO toxicity > 1.

Response to salvage therapy was assessed according to the criteria of the European Group for Blood and Marrow Transplantation (EBMT).³

View Large

This Feature Is Available To Subscribers Only